Biomednewsbreaks - Nanoviricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
NanoViricides, Inc. (NYSE American: NNVC) has filed its quarterly report for the period ending Dec. 31, 2024, with the SEC, reporting cash and cash e ...
NanoViricides reports Q2 EPS (14c) vs. (18c) last year
The company said, “We reported that, as of December 31, 2024, we had cash and cash equivalent current assets balance of approximately $3.96 ...
NanoViricides, Inc. Has Filed its Quarterly Report
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
NanoViricides: Fiscal Q2 Earnings Snapshot
(NNVC) on Friday reported a loss of $2 million in its fiscal second quarter. On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 14 cents. This story was generated by ...
Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?
We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at ...